Treatment of levodopa-induced dyskinesias with donepezil

Parkinsonism and Related Disorders

Volumn 12, Issue 4, 2006, Pages 261-263

  Caroff, Stanley N ^a,c   Martine, Rebecca ^b   Kleiner Fisman, Galit ^b,c   Eisa, Mahmood ^d   Lorry, Alan ^a   Gallop, Robert ^e   Stern, Matthew B ^b,c   Duda, John E ^b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Education and Clinical Center   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WEST CHESTER UNIVERSITY   (United States)

Author keywords

Cholinesterase inhibitors; Donepezil; Dyskinesias; Levodopa; Parkinson's disease

Indexed keywords

AMANTADINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA;

ADULT; AGED; BRAIN NERVE CELL; CATALEPSY; CHOLINERGIC ACTIVITY; CHOLINERGIC NERVE CELL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG DOSE REGIMEN; DRUG TREATMENT FAILURE; DYSKINESIA; HUMAN; HYPOTHESIS; LETTER; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; SCORING SYSTEM; SYNAPTIC MEMBRANE;

AGED; ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; INDANS; LEVODOPA; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PIPERIDINES;

EID: 33646689598     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2005.10.003     Document Type: Letter

References (12)

1. Rascol O. l-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach. Mov Disord 14 (1999) 19-32
2. Zhou F.M., Wilson C., and Dani J.A. Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Neuroscientist 9 (2003) 23-36
3. Lindeboom S.F., and Lakke J.P.W.F. Deanol and physostigmine in the treatment of l-dopa-induced dyskinesias. Acta Neurol Scand 58 (1978) 134-138
4. Miller R., and Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and l-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 34 (1993) 713-738
5. Hobson D.E., Lang A.E., Martin W.R.W., Razmy A., Rivest J., and Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson's disease. A survey by the Canadian Movement Disorders group. JAMA 287 (2002) 455-464
6. Tarsy D., Leopold N., and Sax D.S. Physostigmine in choreiform movement disorders. Neurology 24 (1974) 28-33
7. Clough C.G., Bergmann K.J., and Yahr M.D. Cholinergic and dopaminergic mechanisms in Parkinson's disease after long-term l-DOPA administration. Adv Neurol 40 (1984) 131-140
8. Ott B.R., and Lannon M.C. Exacerbation of Parkinsonism by tacrine. Clin Neuropharmacol 15 (1992) 322-325
9. Bourke D., and Druckenbrod R.W. Possible association between donepezil and worsening Parkinson's disease. Ann Pharmacother 32 (1998) 610-611
10. Richard I.H., Justus A.W., Greig N.H., Marshall F., and Kurlan R. Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine. Clin Neuropharmacol 25 (2002) 296-299
11. Aarsland D., Laake K., Larsen J.P., and Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomized controlled study. J Neurol Neurosurg Psychiatry 72 (2002) 708-712
12. Ravina B., Putt M., Siderowf A., Farrar J.T., Gillespie M., Crawley A., Fernandez H.H., Trieschmann M.M., Reichwein S., and Simuni T. Donepezil for dementia in Parkinson's disease: a randomized, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 76 (2005) 934-939